MyoKardia, Inc. (NASDAQ:MYOK) had its target price upped by equities researchers at Cowen and Company from $28.00 to $56.00 in a research report issued on Monday. Cowen and Company’s target price would indicate a potential upside of 78.06% from the company’s current price.

MYOK has been the subject of several other research reports. BidaskClub raised shares of MyoKardia from a “buy” rating to a “strong-buy” rating in a research note on Saturday. TheStreet cut shares of MyoKardia from a “c-” rating to a “d+” rating in a research note on Friday, May 19th. Zacks Investment Research cut shares of MyoKardia from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. BMO Capital Markets reissued an “outperform” rating and issued a $32.00 price target on shares of MyoKardia in a research note on Wednesday, May 10th. Finally, ValuEngine raised shares of MyoKardia from a “sell” rating to a “hold” rating in a research note on Monday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. MyoKardia has a consensus rating of “Buy” and an average price target of $35.00.

MyoKardia (NASDAQ MYOK) traded up 83.38% on Monday, reaching $31.45. The company had a trading volume of 8,757,035 shares. The firm’s market capitalization is $989.26 million. MyoKardia has a 1-year low of $10.55 and a 1-year high of $32.30. The company’s 50-day moving average price is $14.02 and its 200 day moving average price is $13.13.

MyoKardia (NASDAQ:MYOK) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.04. MyoKardia had a negative net margin of 39.44% and a negative return on equity of 15.27%. The business had revenue of $5.60 million for the quarter, compared to analysts’ expectations of $6.73 million. During the same period in the prior year, the company posted ($0.37) EPS. The firm’s revenue was up 60.0% on a year-over-year basis. On average, equities analysts forecast that MyoKardia will post ($1.54) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “MyoKardia, Inc. (NASDAQ:MYOK) Given New $56.00 Price Target at Cowen and Company” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/07/myokardia-inc-nasdaqmyok-given-new-56-00-price-target-at-cowen-and-company.html.

In other news, CEO Anastasios Gianakakos sold 4,300 shares of the stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $16.62, for a total value of $71,466.00. Following the completion of the sale, the chief executive officer now owns 512,463 shares of the company’s stock, valued at approximately $8,517,135.06. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 46.10% of the company’s stock.

Several hedge funds have recently bought and sold shares of MYOK. Highbridge Capital Management LLC purchased a new stake in MyoKardia during the first quarter valued at $136,000. Casdin Capital LLC purchased a new stake in MyoKardia during the fourth quarter valued at $5,921,000. Trexquant Investment LP boosted its stake in MyoKardia by 134.5% in the first quarter. Trexquant Investment LP now owns 37,987 shares of the biotechnology company’s stock valued at $500,000 after buying an additional 21,787 shares during the period. A.R.T. Advisors LLC purchased a new stake in MyoKardia during the fourth quarter valued at $148,000. Finally, Bank of New York Mellon Corp boosted its stake in MyoKardia by 84.7% in the second quarter. Bank of New York Mellon Corp now owns 21,503 shares of the biotechnology company’s stock valued at $267,000 after buying an additional 9,861 shares during the period. 47.74% of the stock is owned by institutional investors and hedge funds.

About MyoKardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.